NDC Package 73491-627-01 Ryzneuta

Efbemalenograstim Alfa-vuxw Injection Subcutaneous - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
73491-627-01
Package Description:
1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE
Product Code:
Proprietary Name:
Ryzneuta
Non-Proprietary Name:
Efbemalenograstim Alfa-vuxw
Substance Name:
Efbemalenograstim Alfa
Usage Information:
RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Limitations of UseRYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
11-Digit NDC Billing Format:
73491062701
NDC to RxNorm Crosswalk:
  • RxCUI: 2670662 - efbemalenograstim alfa-vuxw 20 MG in 1 ML Prefilled Syringe
  • RxCUI: 2670662 - 1 ML efbemalenograstim alfa-vuxw 20 MG/ML Prefilled Syringe
  • RxCUI: 2670662 - efbemalenograstim alfa-vuxw 20 MG per 1 ML Prefilled Syringe
  • RxCUI: 2670669 - Ryzneuta 20 MG in 1 ML Prefilled Syringe
  • RxCUI: 2670669 - 1 ML efbemalenograstim alfa-vuxw 20 MG/ML Prefilled Syringe [Ryzneuta]
  • Product Type:
    Human Prescription Drug
    Labeler Name:
    Evive Biotechnology Singapore Pte. Ltd.
    Dosage Form:
    Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
    Administration Route(s):
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
  • Active Ingredient(s):
    Sample Package:
    No
    FDA Application Number:
    BLA761134
    Marketing Category:
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date:
    11-23-2023
    Listing Expiration Date:
    12-31-2025
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 73491-627-01?

    The NDC Packaged Code 73491-627-01 is assigned to a package of 1 syringe in 1 carton / 1 ml in 1 syringe of Ryzneuta, a human prescription drug labeled by Evive Biotechnology Singapore Pte. Ltd.. The product's dosage form is injection and is administered via subcutaneous form.

    Is NDC 73491-627 included in the NDC Directory?

    Yes, Ryzneuta with product code 73491-627 is active and included in the NDC Directory. The product was first marketed by Evive Biotechnology Singapore Pte. Ltd. on November 23, 2023 and its listing in the NDC Directory is set to expire on December 31, 2025 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 73491-627-01?

    The 11-digit format is 73491062701. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-273491-627-015-4-273491-0627-01